98 related articles for article (PubMed ID: 8543420)
1. Malignant hemangioendothelioma.
Ihda H; Tokura Y; Fushimi M; Yokote R; Hashizume H; Shirahama S; Iwatsuki K; Murakami K; Takigawa M
Int J Dermatol; 1995 Nov; 34(11):811-6. PubMed ID: 8543420
[TBL] [Abstract][Full Text] [Related]
2. A case of malignant haemangioendothelioma treated with recombinant interleukin-2.
Ansai S; Goto K; Aoki T; Hozumi Y; Aso K
Clin Exp Dermatol; 1993 Sep; 18(5):470-5. PubMed ID: 8252775
[TBL] [Abstract][Full Text] [Related]
3. Identification of a novel CD56- lymphokine-activated killer cell precursor in cancer patients receiving recombinant interleukin 2.
McKenzie RS; Simms PE; Helfrich BA; Fisher RI; Ellis TM
Cancer Res; 1992 Nov; 52(22):6318-22. PubMed ID: 1384959
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of recombinant interleukin-2 immunotherapy for human hemangiosarcoma in a SCID mice model (WB-SCID).
Masuzawa M; Mochida N; Amano T; Fujimura T; Hamada Y; Tamauchi H; Sakurai Y; Nishiyama S; Katsuoka K
J Dermatol Sci; 2001 Oct; 27(2):88-94. PubMed ID: 11532372
[TBL] [Abstract][Full Text] [Related]
5. Independent expression of p55 and p75 interleukin-2 receptors (IL-2R) during intravenous or subcutaneous administration of recombinant interleukin-2 (rIL-2) by T-lymphocytes and natural killer cells.
Zambello R; Trentin L; Cerutti A; Enthammer C; Milani A; Franceschi T; Messina C; Cetto GL; Agostini C; Semenzato G
Cancer; 1994 Nov; 74(9):2562-9. PubMed ID: 7522954
[TBL] [Abstract][Full Text] [Related]
6. [A case of malignant hemangioendothelioma effectively treated with intra-arterial continuous infusion of interleukin-2].
Fujioka A; Sezai Y
Nihon Hifuka Gakkai Zasshi; 1991 Aug; 101(9):959-63. PubMed ID: 1942594
[TBL] [Abstract][Full Text] [Related]
7. [Strategy of cancer treatment using human recombinant interleukin 2 and lymphokine activated killer cells].
Saijo N; Ozaki A; Ishihara J; Sakurai M; Sasaki Y; Takahashi H; Sano T; Hoshi A
Gan To Kagaku Ryoho; 1986 Apr; 13(4 Pt 2):1290-7. PubMed ID: 3488026
[TBL] [Abstract][Full Text] [Related]
8. Effects of systemic recombinant interleukin-2 on natural killer and lymphokine activated killer activity of human tumor infiltrating lymphocytes.
Anderson TM; Ibayashi Y; Tokuda Y; Colquhoun SD; Holmes EC; Golub SH
Cancer Res; 1988 Mar; 48(5):1180-3. PubMed ID: 3257716
[TBL] [Abstract][Full Text] [Related]
9. Intralesional infusion of lymphokine-activated killer (LAK) cells and recombinant interleukin-2 (rIL-2) for the treatment of patients with malignant brain tumor.
Merchant RE; Merchant LH; Cook SH; McVicar DW; Young HF
Neurosurgery; 1988 Dec; 23(6):725-32. PubMed ID: 2851116
[TBL] [Abstract][Full Text] [Related]
10. [Immunohistology of tumor tissue in local administration of recombinant interleukin-2 in head and neck cancer].
Saito T; Kawaguti T; Yoda J; Kimura T; Tabata T
Nihon Jibiinkoka Gakkai Kaiho; 1989 Aug; 92(8):1271-6. PubMed ID: 2685216
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy with intralesional and systemic interleukin-2 of patients with non-small-cell lung cancer.
Scudeletti M; Filaci G; Imro MA; Motta G; Di Gaetano M; Pierri I; Tongiani S; Indiveri F; Puppo F
Cancer Immunol Immunother; 1993 Jul; 37(2):119-24. PubMed ID: 8391391
[TBL] [Abstract][Full Text] [Related]
12. In vivo and in vitro activation of natural killer cells in advanced cancer patients undergoing combined recombinant interleukin-2 and LAK cell therapy.
Phillips JH; Gemlo BT; Myers WW; Rayner AA; Lanier LL
J Clin Oncol; 1987 Dec; 5(12):1933-41. PubMed ID: 3500280
[TBL] [Abstract][Full Text] [Related]
13. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
14. Phase I trial of intraperitoneal recombinant interleukin-2/lymphokine-activated killer cells in patients with ovarian cancer.
Stewart JA; Belinson JL; Moore AL; Dorighi JA; Grant BW; Haugh LD; Roberts JD; Albertini RJ; Branda RF
Cancer Res; 1990 Oct; 50(19):6302-10. PubMed ID: 2205379
[TBL] [Abstract][Full Text] [Related]
15. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
16. Lack of correlation between peripheral blood lymphokine-activated killer (LAK) cell function and clinical response in patients with advanced malignant melanoma receiving recombinant interleukin 2.
Ghosh AK; Dazzi H; Thatcher N; Moore M
Int J Cancer; 1989 Mar; 43(3):410-4. PubMed ID: 2784419
[TBL] [Abstract][Full Text] [Related]
17. [A dramatic effect of continuous intra-arterial injected recombinant interleukin-2 immunotherapy on malignant hemangioendothelioma].
Takano M; Suzuki Y; Asai T; Masuzawa M; Nishiyama S
Nihon Hifuka Gakkai Zasshi; 1991 Jun; 101(7):719-25. PubMed ID: 1942580
[TBL] [Abstract][Full Text] [Related]
18. Lymphokine-activated killer cells in rats. IV. Developmental relationships among large agranular lymphocytes, large granular lymphocytes, and lymphokine-activated killer cells.
Maghazachi AA; Vujanovic NL; Herberman RB; Hiserodt JC
J Immunol; 1988 Apr; 140(8):2846-52. PubMed ID: 3258622
[TBL] [Abstract][Full Text] [Related]
19. Adoptive immunotherapy of murine hepatic metastases with lymphokine activated killer (LAK) cells and recombinant interleukin 2 (RIL 2) can mediate the regression of both immunogenic and nonimmunogenic sarcomas and an adenocarcinoma.
Lafreniere R; Rosenberg SA
J Immunol; 1985 Dec; 135(6):4273-80. PubMed ID: 3877766
[TBL] [Abstract][Full Text] [Related]
20. Lymphokine-activated killer cells in rats: analysis of progenitor and effector cell phenotype and relationship to natural killer cells.
Vujanovic NL; Herberman RB; Olszowy MW; Cramer DV; Salup RR; Reynolds CW; Hiserodt JC
Cancer Res; 1988 Feb; 48(4):884-90. PubMed ID: 3257412
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]